Company Profile
Sight Sciences Stock Price, News & Analysis
- Ticker:
- SGHT
- Exchange:
- NASDAQ
- Sector:
- MedTech
- Location:
- United States
Stock performance
7.09 USD (+27.75%)
Close
Last updated: August 6, 2026
236M USD
Market cap
Why the stock is moving
Following the latest company update, “Sight Sciences Reports Second Quarter 2026 Financial Results”, SGHT closed up 27.7% at $7.09 on Aug 6, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Interventional Eye Care
Sight Sciences develops minimally invasive and noninvasive technologies intended to address underlying causes of glaucoma and dry-eye disease.
Glaucoma Systems
OMNI and OMNI Edge are implant-free minimally invasive glaucoma-surgery systems that access Schlemm's canal and the trabecular meshwork. SION is a bladeless device used to excise trabecular meshwork.
TearCare
TearCare applies localized heat to the eyelids so physicians can clear obstructed meibomian glands, addressing a major cause of evaporative dry-eye disease.
Future catalysts
Sight Sciences's catalysts are TearCare adoption, glaucoma-product execution, and any procedure-based growth update. The company improves when the procedure base keeps widening.
Recent news
- 01
Sight Sciences Reports Second Quarter 2026 Financial Results
Source: Sight Sciences
- 02
Sight Sciences Announces Aetna Coverage for OMNI and SION Surgical Systems
Source: Sight Sciences
- 03
Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System
Source: Sight Sciences
- 04
Sight Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026
Source: Sight Sciences
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Sight Sciences (SGHT)?
Sight Sciences (SGHT) most recently closed at 7.09 USD, a +27.75% move versus the previous session.
What is the market cap of Sight Sciences (SGHT)?
Sight Sciences currently has a market capitalization of 236M USD on BioPharmSignal.
What does Sight Sciences do?
Interventional Eye Care Sight Sciences develops minimally invasive and noninvasive technologies intended to address underlying causes of glaucoma and dry-eye disease. Glaucoma Systems OMNI and OMNI Edge are implant-free minimally invasive glaucoma-surgery systems that access Schlemm's canal and the trabecular meshwork. SION is a bladeless device used to...
On which exchange is SGHT stock listed?
Sight Sciences (SGHT) is associated with NASDAQ, United States, MedTech.
What is Interventional?
Interventional Eye Care Sight Sciences develops minimally invasive and noninvasive technologies intended to address underlying causes of glaucoma and dry-eye disease.
Which conditions is Sight Sciences targeting with Interventional?
Interventional Eye Care Sight Sciences develops minimally invasive and noninvasive technologies intended to address underlying causes of glaucoma and dry-eye disease. Glaucoma Systems OMNI and OMNI Edge are implant-free minimally invasive glaucoma-surgery systems that access Schlemm's canal and the trabecular meshwork. SION is a bladeless device used to...
How does Sight Sciences describe recent progress with Interventional?
Sight Sciences's catalysts are TearCare adoption, glaucoma-product execution, and any procedure-based growth update. The company improves when the procedure base keeps widening.
What is Care?
Interventional Eye Care Sight Sciences develops minimally invasive and noninvasive technologies intended to address underlying causes of glaucoma and dry-eye disease.